Pietro Genovese
Overview
Explore the profile of Pietro Genovese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
2425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klatt D, Sereni L, Liu B, Genovese P, Schambach A, Verhoeyen E, et al.
Mol Ther Nucleic Acids
. 2024 Dec;
35(4):102389.
PMID: 39679008
The baboon endogenous retrovirus (BaEV) glycoprotein is superior to the commonly used vesicular stomatitis virus glycoprotein (VSVg) for retroviral gene transfer into resting hematopoietic stem cells and lymphocyte populations. The...
2.
Montepeloso A, Mattioli D, Pellin D, Peviani M, Genovese P, Biffi A
Nat Commun
. 2024 Nov;
15(1):10192.
PMID: 39587072
Transplantation of engineered hematopoietic stem/progenitor cells (HSPCs) showed curative potential in patients affected by neurometabolic diseases treated in early stage. Favoring the engraftment and maturation of the engineered HSPCs in...
3.
Landoni E, Woodcock M, Barragan G, Casirati G, Cinella V, Stucchi S, et al.
Nat Commun
. 2024 Jun;
15(1):5182.
PMID: 38890345
No abstract available.
4.
Levesque S, Cosentino A, Verma A, Genovese P, Bauer D
Nat Biotechnol
. 2024 May;
PMID: 38806736
Therapeutic prime editing of hematopoietic stem and progenitor cells (HSPCs) holds great potential to remedy blood disorders. Quiescent cells have low nucleotide levels and resist retroviral infection, and it is...
5.
Cianciotti B, Magnani Z, Ugolini A, Camisa B, Merelli I, Vavassori V, et al.
Front Immunol
. 2024 Mar;
15:1315283.
PMID: 38510235
Background: In adoptive T cell therapy, the long term therapeutic benefits in patients treated with engineered tumor specific T cells are limited by the lack of long term persistence of...
6.
Castiello M, Brandas C, Ferrari S, Porcellini S, Sacchetti N, Canarutto D, et al.
Sci Transl Med
. 2024 Feb;
16(733):eadh8162.
PMID: 38324638
Recombination activating genes () are tightly regulated during lymphoid differentiation, and their mutations cause a spectrum of severe immunological disorders. Hematopoietic stem and progenitor cell (HSPC) transplantation is the treatment...
7.
Landoni E, Woodcock M, Barragan G, Casirati G, Cinella V, Stucchi S, et al.
Nat Commun
. 2024 Jan;
15(1):89.
PMID: 38167707
Human natural killer T cells (NKTs) are innate-like T lymphocytes increasingly used for cancer immunotherapy. Here we show that human NKTs expressing the pro-inflammatory cytokine interleukin-12 (IL-12) undergo extensive and...
8.
Casirati G, Cosentino A, Mucci A, Salah Mahmoud M, Ugarte Zabala I, Zeng J, et al.
Nature
. 2023 Aug;
621(7978):404-414.
PMID: 37648862
Despite the considerable efficacy observed when targeting a dispensable lineage antigen, such as CD19 in B cell acute lymphoblastic leukaemia, the broader applicability of adoptive immunotherapies is hampered by the...
9.
Zeng J, Casirati G, Nguyen M, Genovese P, Bauer D
Methods Mol Biol
. 2023 Jan;
2606:43-62.
PMID: 36592307
Base editing by nucleotide deaminases linked to programmable DNA-binding proteins represents a promising approach to remedy blood disorders. Here we describe the ex vivo base editing of human CD34+ hematopoietic...
10.
Costantino C, Cimino L, Bonaccorso N, Conforto A, Sciortino M, Blangiardi F, et al.
Hum Vaccin Immunother
. 2022 Nov;
18(6):2141998.
PMID: 36330584
Hexavalent (HV) vaccination is a priority for newborn protection and in Italy is included in the National Immunization Plan with a three doses cycle at 61, 121 and 301 days...